Crinetics Pharmaceuticals, Inc.CRNXNASDAQ
LOADING
|||
Price to Sales: Premium Valuation
Trending higher, above historical average, strong compound growth.
Left:
||||
Price-to-sales ratio
Latest
3975.39
↑ 172% above average
Average (8y)
1461.92
Historical baseline
Range
High:6051.00
Low:149.97
CAGR
+27.3%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | 3975.39 | +672.1% |
| 2023 | 514.87 | +156.4% |
| 2022 | 200.82 | -80.2% |
| 2021 | 1012.96 | -83.3% |
| 2020 | 6051.00 | +1090.1% |
| 2019 | 508.42 | +239.0% |
| 2018 | 149.97 | -9.8% |
| 2017 | 166.33 | -71.2% |
| 2016 | 577.51 | - |